Immunohistochemistry revealed that A549 cells in the lung cancer model presented high expression of Ki67, a proliferation marker, regardless of gefitinib treatment; whereas PC-9 cells showed a significant decrease in Ki67 expression in the group treated with gefitinib (Figure 6C). This evidence concerns the gene MKI67 and lung cancer.